Bavituximab to Star in Phase II Hepatitis C Trial
Share
Follow Us
Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C
Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care
TUSTIN, CA–(Marketwire – January 10, 2011) – Peregrine Pharmaceuticals, Inc.
(NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine’s bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year.
Continue reading this entire article:
http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm
